Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New chemotherapies in breast cancer

New chemotherapies in breast cancer Summary In the era of targeted therapies and immunotherapy for cancer, the focus in breast cancer (BC) research has shifted away from classical chemotherapy. Many BC patients, however, still need chemotherapy and thus benefit from the development of new chemotherapeutic agents or regimens. In the past decade, the approval of eribulin and trastuzumab emtansine (T-DM1) have been important advances in this regard. Improved ways of delivery of paclitaxel, anthracyclines, and vinorelbine have also had a considerable clinical impact. Finally, optimizing the use of well-known drugs, such as carboplatin, capecitabine, or adjuvant chemoimmunotherapy in low-risk early BC, has brought about progress in the field of chemo(immuno)therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

New chemotherapies in breast cancer

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/new-chemotherapies-in-breast-cancer-QDE7gjPl6Q
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0348-y
Publisher site
See Article on Publisher Site

Abstract

Summary In the era of targeted therapies and immunotherapy for cancer, the focus in breast cancer (BC) research has shifted away from classical chemotherapy. Many BC patients, however, still need chemotherapy and thus benefit from the development of new chemotherapeutic agents or regimens. In the past decade, the approval of eribulin and trastuzumab emtansine (T-DM1) have been important advances in this regard. Improved ways of delivery of paclitaxel, anthracyclines, and vinorelbine have also had a considerable clinical impact. Finally, optimizing the use of well-known drugs, such as carboplatin, capecitabine, or adjuvant chemoimmunotherapy in low-risk early BC, has brought about progress in the field of chemo(immuno)therapy.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Sep 1, 2017

References

  • Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    J Cortes, J O’Shaughnessy, D Loesch, JL Blum, LT Vahdat, K Petrakova
  • Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
    PA Kaufman, A Awada, C Twelves, L Yelle, EA Perez, G Velikova
  • Results of a phase II study of maytansine in patients with breast carcinoma and melanoma
    F Cabanillas, GP Bodey, MA Burgess, EJ Freireich
  • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    DJ Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde
  • Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2‑positive breast cancer
    SJ Isakoff, J Baselga
  • Trastuzumab emtansine for HER2-positive advanced breast cancer
    S Verma, D Miles, L Gianni, IE Krop, M Welslau, J Baselga
  • Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
    IE Krop, SB Kim, A Gonzalez-Martin, PM LoRusso, JM Ferrero, M Smitt
  • Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2‑positive, advanced breast cancer: primary results from the phase III MARIANNE study
    EA Perez, C Barrios, W Eiermann, M Toi, YH Im, P Conte
  • Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
    SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone
  • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
    WJ Gradishar, S Tjulandin, N Davidson, H Shaw, N Desai, P Bhar
  • Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel
    N Desai, V Trieu, Z Yao, L Louie, S Ci, A Yang
  • Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial
    M Untch, C Jackisch, A Schneeweiss, B Conrad, B Aktas, C Denkert
  • ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: a MICHELANGO study
    L Gianni, M Mansutti, A Anton
  • Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
    DA Yardley, A Brufsky, RE Coleman, PF Conte, J Cortes, S Gluck
  • Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial
    H Kreipe
  • Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre
    S Dent, J Fraser, N Graham, M Campbell, S Hopkins, G Dranitsaris
  • Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia
    AE Lohmann, CH Speers, SK Chia
  • Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis
    Y Zong, J Wu, K Shen
  • Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
    SM Swain, FS Whaley, MS Ewer
  • Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
    L Harris, G Batist, R Belt, D Rovira, R Navari, N Azarnia
  • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
    ME O’Brien, N Wigler, M Inbar, R Rosso, E Grischke, A Santoro
  • Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials
    M Xing, F Yan, S Yu, P Shen
  • A systematic review of vinorelbine for the treatment of breast cancer
    YC Xu, HX Wang, L Tang, Y Ma, FC Zhang
  • Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results
    M Aapro, J Finek
  • Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
    EA Perez, A Awada, J O’Shaughnessy, HS Rugo, C Twelves, SA Im
  • Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer
    ML Telli, KM Timms, J Reid, B Hennessy, GB Mills, KC Jensen
  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto
    G Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai
  • Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC)
    CE Geyer, J O’Shaughnessy, M Untch, W Sikov, HS Rugo, MD McKee
  • Adjuvant capecitabine for breast cancer after preoperative chemotherapy
    N Masuda, SJ Lee, S Ohtani, YH Im, ES Lee, I Yokota
  • Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups
    JG Shin, HS Cheong, JY Kim, LH Kim, CS Han, JO Kim
  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, I Smith
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
    SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom